PURPOSE: Intravenous methotrexate (IV-MTX), an effective treatment for acute lymphoblastic leukemia (ALL), has a significant toxic effect on the central nervous system, with leukoencephalopathy (LE) being the most common form. The purpose of this study was to use objective quantitative MR imaging to prospectively assess the temporal evolution of LE extent and intensity. METHODS: Forty-five children (low-risk, 10 mol/L/12F; mean age, 5.0 years at diagnosis; standard/high-risk, 11 mol/L/12F; mean age, 9.2 years at diagnosis) treated for ALL on a single institutional protocol were evaluated longitudinally to assess the extent of LE (proportion of white matter impacted) through tissue segmentation and the relative intensity of LE through relative elevations in T1 and T2 relaxation rates. One-sided Wilcoxon-Mann-Whitney tests were used to assess differences in quantitative measures at 4 different points in therapy both within and between risk arms. RESULTS: The proportion of white matter affected in both patient groups increased significantly with additional courses of IV-MTX, whereas the intensity of LE also increased steadily; however, both the intensity and extent of LE declined significantly approximately 1.5 years after completion of IV-MTX. Increases in the T1 and T2 relaxation rates above normal-appearing white matter were significantly correlated with each other and were dependent on the proportion of white matter affected. CONCLUSION: Higher doses and more courses of IV-MTX were associated with increased intensity and extent of LE. There was a significant reduction in both the intensity and extent of LE after completion of therapy. The impact of these changes on neurocognitive functioning and quality of life in survivors remains to be determined.
PURPOSE: Intravenous methotrexate (IV-MTX), an effective treatment for acute lymphoblastic leukemia (ALL), has a significant toxic effect on the central nervous system, with leukoencephalopathy (LE) being the most common form. The purpose of this study was to use objective quantitative MR imaging to prospectively assess the temporal evolution of LE extent and intensity. METHODS: Forty-five children (low-risk, 10 mol/L/12F; mean age, 5.0 years at diagnosis; standard/high-risk, 11 mol/L/12F; mean age, 9.2 years at diagnosis) treated for ALL on a single institutional protocol were evaluated longitudinally to assess the extent of LE (proportion of white matter impacted) through tissue segmentation and the relative intensity of LE through relative elevations in T1 and T2 relaxation rates. One-sided Wilcoxon-Mann-Whitney tests were used to assess differences in quantitative measures at 4 different points in therapy both within and between risk arms. RESULTS: The proportion of white matter affected in both patient groups increased significantly with additional courses of IV-MTX, whereas the intensity of LE also increased steadily; however, both the intensity and extent of LE declined significantly approximately 1.5 years after completion of IV-MTX. Increases in the T1 and T2 relaxation rates above normal-appearing white matter were significantly correlated with each other and were dependent on the proportion of white matter affected. CONCLUSION: Higher doses and more courses of IV-MTX were associated with increased intensity and extent of LE. There was a significant reduction in both the intensity and extent of LE after completion of therapy. The impact of these changes on neurocognitive functioning and quality of life in survivors remains to be determined.
Authors: Isabelle Montour-Proulx; Sally M Kuehn; Daniel L Keene; Nicholas J Barrowman; Elizabeth Hsu; Mary-Ann Matzinger; Hal Dunlap; Jacqueline M Halton Journal: J Child Neurol Date: 2005-02 Impact factor: 1.987
Authors: Wilburn E Reddick; John O Glass; Kathleen J Helton; James W Langston; Xiaoping Xiong; Shengjie Wu; Ching-Hon Pui Journal: AJNR Am J Neuroradiol Date: 2005-05 Impact factor: 3.825
Authors: R G Steen; S A Gronemeyer; P B Kingsley; W E Reddick; J S Langston; J S Taylor Journal: J Magn Reson Imaging Date: 1994 Sep-Oct Impact factor: 4.813
Authors: Wilburn E Reddick; Zuyao Y Shan; John O Glass; Susan Helton; Xiaoping Xiong; Shengjie Wu; Melanie J Bonner; Scott C Howard; Robbin Christensen; Raja B Khan; Ching-Hon Pui; Raymond K Mulhern Journal: Cancer Date: 2006-02-15 Impact factor: 6.860
Authors: Jason Ashford; Corrie Schoffstall; Wilburn E Reddick; Christina Leone; Fred H Laningham; John O Glass; Deqing Pei; Cheng Cheng; Ching-Hon Pui; Heather M Conklin Journal: Cancer Date: 2010-10-01 Impact factor: 6.860
Authors: Deepa Bhojwani; Noah D Sabin; Deqing Pei; Jun J Yang; Raja B Khan; John C Panetta; Kevin R Krull; Hiroto Inaba; Jeffrey E Rubnitz; Monika L Metzger; Scott C Howard; Raul C Ribeiro; Cheng Cheng; Wilburn E Reddick; Sima Jeha; John T Sandlund; William E Evans; Ching-Hon Pui; Mary V Relling Journal: J Clin Oncol Date: 2014-02-18 Impact factor: 44.544
Authors: Wilburn E Reddick; Delaram J Taghipour; John O Glass; Jason Ashford; Xiaoping Xiong; Shengjie Wu; Melanie Bonner; Raja B Khan; Heather M Conklin Journal: Pediatr Blood Cancer Date: 2014-01-25 Impact factor: 3.167
Authors: Michelle N Edelmann; Robert J Ogg; Matthew A Scoggins; Tara M Brinkman; Noah D Sabin; Ching-Hon Pui; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Pediatr Blood Cancer Date: 2013-06-18 Impact factor: 3.167
Authors: Ellen van der Plas; Brian J Nieman; Darci T Butcher; Johann K Hitzler; Rosanna Weksberg; Shinya Ito; Russell Schachar Journal: J Can Acad Child Adolesc Psychiatry Date: 2015-03-04